• In February 2026, Arcutis Biotherapeutics reported fourth-quarter 2025 revenue of US$129.5 million and full-year revenue of US$376.07 million, moved to a Q4 net profit of US$17.4 million, and raised its 2026 net product revenue guidance to US$480 million–US$495 million while filing an omnibus shelf registration for multiple securities.
• The results highlight how rapid uptake of ZORYVE across expanded indications, including pediatric use, is beginning to translate into improving profitability and funding flexibility for Arcutis’s dermatology-focused expansion.
• We’ll now explore how Arcutis’s higher 2026 revenue guidance and improving cash generation shape, and potentially strengthen, its investment narrative.

Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 31 best rare earth metal stocks of the very few that mine this essential strategic resource.

Arcutis Biotherapeutics Investment Narrative Recap

To stay invested in Arcutis, you need to believe that ZORYVE can sustain prescription momentum across more skin conditions and age groups, while the rest of the pipeline gradually contributes. The Q4 move to profitability and higher 2026 revenue guidance support that near term, but also sharpen the key risk that the business is still heavily concentrated in a single franchise that must keep performing as competition and payer pressures evolve.

The new omnibus shelf registration sits alongside the raised 2026 revenue guidance as an important context point: Arcutis has just shown it can generate positive cash flow, yet is also putting flexible funding tools in place for future needs. For investors, that combination ties directly back to the main catalyst of ZORYVE’s expanded commercial rollout and the ongoing requirement to invest in R&D and promotion without undermining recent profitability gains.

Yet while revenue guidance has moved higher, investors should also be aware of...

Arcutis Biotherapeutics' narrative projects $676.8 million revenue and $237.0 million earnings by 2028. This requires 37.0% yearly revenue growth and about a $330 million earnings increase from $-93.3 million today.

Uncover how Arcutis Biotherapeutics' forecasts yield a $31.75 fair value, a 18% upside to its current price.

Exploring Other Perspectives

Six fair value estimates from the Simply Wall St Community span roughly US$18 to almost US$90 per share, underlining how far apart views on Arcutis can be. Against that backdrop, the company’s raised 2026 revenue guidance and recent swing to quarterly profitability give you additional context for weighing ZORYVE concentration risk and its potential impact on future performance.

Explore 6 other fair value estimates on Arcutis Biotherapeutics - why the stock might be worth 33% less than the current price!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Arcutis Biotherapeutics research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Arcutis Biotherapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Arcutis Biotherapeutics' overall financial health at a glance.

Interested In Other Possibilities?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• Capitalize on the AI infrastructure supercycle with our selection of the 33 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Invest in the nuclear renaissance through our list of 84 elite nuclear energy infrastructure plays powering the global AI revolution.
• Find 46 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.